Elyxium Wealth’s Xenon Pharmaceuticals XENE Stock Holding History

Elyxium Wealth’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.12K	Buy	+57	New	+$3.39K	﹤0.01%	1304

Other funds holding XENE

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Elmwood Wealth Management Berkeley, California $416M AUM 11.87% 1-Year Est. Return

Elyxium Wealth's XENE Position: Q3 2026 in Review

Elyxium Wealth opened a new position in Xenon Pharmaceuticals (XENE) in Q3 2026: 57 shares worth $2.12K. The stake represents ﹤0.01% of the portfolio and ranks #1304 among its holdings.

34 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

Elyxium Wealth held 57 shares of Xenon Pharmaceuticals worth $2.12K as of Q3 2026.
Xenon Pharmaceuticals was a new Elyxium Wealth position in Q3 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Elyxium Wealth's portfolio in Q3 2026, its #1304 holding.
34 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Elyxium Wealth's 13F filing for Q3 2026, filed 27 Oct 2026.